Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - May 2015, Vol 8, No 2

  • Dinutuximab FDA-Approved for Pediatric Patients with High-Risk Neuroblastoma
  • First HDAC Inhibitor, Panobinostat, Approved for Patients with Multiple Myeloma
  • Palbociclib Approved for Metastatic Breast Cancer in Postmenopausal Women
  • FDA Expedites Approval of Lenvatinib for Refractory Differentiated Thyroid Cancer
  • Nivolumab First Immunotherapy to Get FDA Approval for Metastatic Lung Cancer
  • Lenalidomide Combined with Dexamethasone Receives Expanded Indication for Patients with Newly Diagnosed Myeloma
In this month’s issue ofThe Oncology Pharmacist (TOP), we present our coverage of the news from the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference. TOP was there, and we highlight presentations about the role of pharmacists in hospice and palliative care, the disposal of oral cancer drugs, and opportunities in survivorship care.
We see a number of changes you might make to improve your financial security, but one item is usually beyond your control: your 401(k) plan. Unless you are self-employed, there is practically nothing you can do if your 401(k) has limited investment options, low contribution limits, or tax consequences.
In 1962, President John F. Kennedy challenged Americans to go to the moon within a decade. Apollo 11 accomplished that goal 7 years later. In 2012, inspired by that challenge, the University of Texas MD Anderson Cancer Center launched the Moon Shots Program. This ambitious plan aims to convert scientific discoveries into clinical advances quickly to improve survival rates for several of the deadliest cancers including ovarian cancer, which is our focus this month.
To what extent should the pharmacist be included in hospice and palliative care, and how can their skills and knowledge best be utilized?
Data presented at the 2015 Gastrointestinal Cancers Symposium illustrated that the biosimilar epoetin alfa (HX575, Binocrit) can safely correct anemia and maintain hemoglobin levels.
Initial results of the ASSURE study prove surprising and disappointing.
Results of a phase 3 study of an investigational monoclonal antibody, MABp1 (Xilonix; XBiotech), evaluated for cachexia in metastatic colorectal cancer (CRC), revealed a surprising finding: patients in the experimental arm showed a trend toward increased overall survival (an end point difficult to reach in any treatment-refractory cancer), with pharmacodynamics activity consistent with this result, investigators reported at the 2015 Gastrointestinal Cancers Symposium, held in San Francisco, CA.
Cancer survivors with chronic diseases are falling through the cracks, said Sarah Scarpace, PharmD, MPH, BCOP, at the 11th annual Hematology/Oncology Pharmacy Association conference. When oncologists are no longer managing chronic diseases like diabetes and hypertension, a window of opportunity exists for pharmacists to become involved in multidisciplinary cancer survivorship team models.
A January 14, 2015, report published by the Institute of Medicine (IOM) walks a fine line between the competing clinical data-sharing comfort zones of pharmaceutical companies, physician associations, patient groups, and other advocacy organizations.
Page 2 of 2
Results 11 - 20 of 20